No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma

byTeddy Guo

January 14, 2021

in StudyGraphics

Reading Time: 1 min read

COVID-19 associated with significant mental health issues among college students in America

RelatedReports

The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing

August 28, 2025

StudyGraphics

#VisualAbstract: Perioperative Durvalumab increased Survival in Gastric and Gastroesopha-geal Junction Cancer

August 7, 2025

Significant reduction in prostate screening rates after revised guidelines

Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified

Chronic Disease

Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma

March 13, 2025

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

Prescription of antibiotics for acute respiratory infections increasing

Common hospital complications associated with COVID-19 identified in a retrospective cohort study

Novel coronavirus identified from patients with pneumonia in Wuhan, China

O and Rh– blood groups may be associated with decreased risk for SARS-CoV-2 infection

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports